Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

NCT03581292 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT03581292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03581292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 6, 2018
Completion date
August 20, 2027
Enrollment
38 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma, malignant glioma